We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Cambridge Cognition Holdings Plc | LSE:COG | London | Ordinary Share | GB00B8DV9647 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
1.20 | 2.18% | 56.20 | 54.00 | 55.00 | 54.50 | 54.50 | 54.50 | 21,504 | 16:35:07 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 12.61M | -409k | -0.0117 | -46.58 | 18.99M |
TIDMCOG
Cambridge Cognition Holdings PLC
21 December 2020
Cambridge Cognition Holdings Plc
(" Cambridge Cognition" or the "Company")
Cambridge Cognition wins new digital health contract worth over GBP700,000
Cambridge Cognition Holdings plc (AIM: COG), which develops and markets digital solutions to assess brain health, is pleased to announce that it has won a new contract with a major pharmaceutical client to provide digital assessments of mood and cognition for a depression trial. The contract is worth over GBP700,000 with most of the revenue expected to be recognised in 2021.
Impairments in cognition can persist after recovery from a period of depression and this can contribute to difficulties in reaching a full recovery. So, in efforts to thoroughly assess treatment efficacy, Cambridge Cognition has been contracted to deploy remote assessments of mood and cognition over a 12-month period. The assessments will be delivered on patients' mobile phones with their performance and wellbeing monitored by the pharmaceutical client.
The inclusion of remote and brief assessments during both the core and extension periods of the trial will provide the client with a better understanding of the relationships between mood, cognition and recovery. Cambridge Cognition is in a unique position to support the delivery of this trial with expertise in both gold-standard cognitive assessment and innovative digital health solutions for frequent, remote testing.
Matthew Stork, Chief Executive Officer of Cambridge Cognition, said:
" We are excited to be working with another pharmaceutical company that recognises the importance of frequent objective cognitive assessments in the development of treatments for central nervous system disorders. This new contract further validates the Company's strategy as again we will be configuring existing digital health solutions rather than undertaking bespoke software development. It also further highlights the opportunity available to Cambridge Cognition to provide remote, patient-centred solutions in the CNS market."
For further information, contact:
Cambridge Cognition Holdings PLC Tel: 012 2381 0700 Matthew Stork, Chief Executive Officer press@camcog.com Nick Walters, Chief Financial Officer finnCap Ltd (NOMAD and Joint Broker) Tel: 020 7220 0500 Geoff Nash / Simon Hicks (Corporate Finance) Alice Lane / Sunila de Silva (Corporate Broking) Dowgate Capital Limited (Joint Broker) Tel: 020 3903 7715 David Poutney / James Serjeant IFC Advisory Ltd (Financial PR and IR) Tel: 020 3934 6630 Tim Metcalfe / Graham Herring / Zach Cohen
Notes to Editors
About Cambridge Cognition
Cambridge Cognition is a neuroscience technology company developing digital health products to better understand, detect and treat conditions affecting brain health. The company's software products assess cognitive health in patients worldwide to improve clinical trial outcomes, identify and stratify patients early and improve global efficiency in pharmaceutical and healthcare industries.
For further information visit www.cambridgecognition.com
This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
NRABLBDDRUDDGGG
(END) Dow Jones Newswires
December 21, 2020 02:00 ET (07:00 GMT)
1 Year Cambridge Cognition Chart |
1 Month Cambridge Cognition Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions